PuREC

About PuREC

PuREC Co., Ltd. is a Japanese biotechnology company focused on regenerative medicine through its proprietary stem cell technology. The company was founded in 2016 by Dr. Yumi Matsuzaki, a professor at Shimane University, based on her research for isolating high-purity mesenchymal stem cells (MSCs). PuREC's core technology enables the isolation and cultivation of what it terms "Rapidly Expanding Cells" (REC), an extremely pure population of MSCs extracted from human bone marrow. These cells are characterized by their superior proliferative, differentiative, and migratory capabilities compared to conventional MSCs, offering the potential for safer and more effective cell therapies due to their homogeneity.

The company's business model centers on the research, development, and eventual commercialization of REC-based therapies, often through strategic partnerships. PuREC collaborates with pharmaceutical companies and academic institutions to advance its product pipeline. A key partnership with Mochida Pharmaceutical aims to establish compliant manufacturing processes for REC-based products. The company's revenue model is expected to be based on licensing its technology, development partnerships, and eventually, the sale of therapeutic products.

PuREC's primary therapeutic focus is on rare and challenging diseases, particularly those related to bone. Its leading product candidate targets hypophosphatasia (HPP), a rare genetic disorder that impairs bone and teeth mineralization. A Phase I/IIa investigator-initiated clinical trial for HPP is underway in Japan, led by Shimane University with government grant support. The company's second target is spinal canal stenosis, a condition causing chronic pain due to the narrowing of the spinal canal. This research is being conducted in collaboration with Hokkaido University and Mochida Pharmaceutical. By developing highly purified stem cell lines, PuREC aims to provide novel, effective, and lower-cost regenerative treatments for a range of conditions.